187 related articles for article (PubMed ID: 36142210)
1. T
Rasé VJ; Hayward R; Haughian JM; Pullen NA
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142210
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of imbalance between Th1 and Th22 cells and its association with disease progression in patients with liver cirrhosis].
Wu HQ; Zhao JJ; Li HW; Zhang Z
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):738-744. PubMed ID: 29108201
[No Abstract] [Full Text] [Related]
3. IL-17/Th17 mediated synovial inflammation is IL-22 independent.
van Hamburg JP; Corneth OB; Paulissen SM; Davelaar N; Asmawidjaja PS; Mus AM; Lubberts E
Ann Rheum Dis; 2013 Oct; 72(10):1700-7. PubMed ID: 23328939
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Le HK; Graham L; Cha E; Morales JK; Manjili MH; Bear HD
Int Immunopharmacol; 2009 Jul; 9(7-8):900-9. PubMed ID: 19336265
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas.
Dawod B; Liu J; Gebremeskel S; Yan C; Sappong A; Johnston B; Hoskin DW; Marshall JS; Wang J
Sci Rep; 2020 Aug; 10(1):13343. PubMed ID: 32770025
[TBL] [Abstract][Full Text] [Related]
6. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Th22, Th17 and CD4
Doulabi H; Rastin M; Shabahangh H; Maddah G; Abdollahi A; Nosratabadi R; Esmaeili SA; Mahmoudi M
Biomed Pharmacother; 2018 Jul; 103():1101-1106. PubMed ID: 29710675
[TBL] [Abstract][Full Text] [Related]
8. Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model.
Khaki Bakhtiarvand V; Ramezani-Ali Akbari K; Amir Jalali S; Hojjat-Farsangi M; Jeddi-Tehrani M; Shokri F; Shabani M
Int Immunopharmacol; 2022 Dec; 113(Pt B):109470. PubMed ID: 36435059
[TBL] [Abstract][Full Text] [Related]
9. Circulating Th22 cells, as well as Th17 cells, are elevated in patients with renal cell carcinoma.
Peng Z; Hu Y; Ren J; Yu N; Li Z; Xu Z
Int J Med Sci; 2021; 18(1):99-108. PubMed ID: 33390778
[TBL] [Abstract][Full Text] [Related]
10. The alteration and clinical significance of Th22/Th17/Th1 cells in patients with chronic myeloid leukemia.
Chen P; Wang M; Li D; Jia Y; He N; Li W; Ma D; Ji C
J Immunol Res; 2015; 2015():416123. PubMed ID: 26000313
[TBL] [Abstract][Full Text] [Related]
11. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer.
Liu T; Peng L; Yu P; Zhao Y; Shi Y; Mao X; Chen W; Cheng P; Wang T; Chen N; Zhang J; Liu X; Li N; Guo G; Tong W; Zhuang Y; Zou Q
J Clin Immunol; 2012 Dec; 32(6):1332-9. PubMed ID: 22760549
[TBL] [Abstract][Full Text] [Related]
12. Prostaglanin-E2 Potentiates the Suppressive Functions of Human Mononuclear Myeloid-Derived Suppressor Cells and Increases Their Capacity to Expand IL-10-Producing Regulatory T Cell Subsets.
Tomić S; Joksimović B; Bekić M; Vasiljević M; Milanović M; Čolić M; Vučević D
Front Immunol; 2019; 10():475. PubMed ID: 30936876
[TBL] [Abstract][Full Text] [Related]
13. Th22 Cells Form a Distinct Th Lineage from Th17 Cells In Vitro with Unique Transcriptional Properties and Tbet-Dependent Th1 Plasticity.
Plank MW; Kaiko GE; Maltby S; Weaver J; Tay HL; Shen W; Wilson MS; Durum SK; Foster PS
J Immunol; 2017 Mar; 198(5):2182-2190. PubMed ID: 28100680
[TBL] [Abstract][Full Text] [Related]
14. Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma.
Wang M; Chen P; Jia Y; He N; Li D; Ji C; Ma D
Oncotarget; 2015 Jul; 6(20):17958-67. PubMed ID: 26255628
[TBL] [Abstract][Full Text] [Related]
15. Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.
Yu S; Liu C; Zhang L; Shan B; Tian T; Hu Y; Shao L; Sun Y; Ji C; Ma D
Int J Mol Sci; 2014 Jan; 15(2):1927-45. PubMed ID: 24473142
[TBL] [Abstract][Full Text] [Related]
16. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.
Bunt SK; Yang L; Sinha P; Clements VK; Leips J; Ostrand-Rosenberg S
Cancer Res; 2007 Oct; 67(20):10019-26. PubMed ID: 17942936
[TBL] [Abstract][Full Text] [Related]
17. "Derived Multiple Allogeneic Protein Paracrine Signaling (d-MAPPS)" Enhances T Cell-Driven Immune Response to Murine Mammary Carcinoma.
Harrell CR; Pavlovic D; Miloradovic D; Stojanovic MD; Djonov V; Volarevic V
Anal Cell Pathol (Amst); 2022; 2022():3655595. PubMed ID: 35757015
[TBL] [Abstract][Full Text] [Related]
18. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
[TBL] [Abstract][Full Text] [Related]
19. Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
Shao LL; Zhang L; Hou Y; Yu S; Liu XG; Huang XY; Sun YX; Tian T; He N; Ma DX; Peng J; Hou M
PLoS One; 2012; 7(12):e51339. PubMed ID: 23236476
[TBL] [Abstract][Full Text] [Related]
20. Increased Th17 and Th22 Cell Percentages Predict Acute Lung Injury in Patients with Sepsis.
Li G; Zhang L; Han N; Zhang K; Li H
Lung; 2020 Aug; 198(4):687-693. PubMed ID: 32462370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
